Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

Zynerba Pharmaceuticals logo

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Advanced Chart

Key Stats

Today's Range
$1.30
$1.30
50-Day Range
$1.21
$1.39
52-Week Range
$0.25
$1.40
Volume
N/A
Average Volume
515,333 shs
Market Capitalization
$70.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
See More Headlines

ZYNE Stock Analysis - Frequently Asked Questions

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

Zynerba Pharmaceuticals (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Cronos Group (CRON), Meta Platforms (META) and Aurora Cannabis (ACB).

Company Calendar

Last Earnings
5/15/2023
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZYNE
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,040,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
1.29

Miscellaneous

Free Float
46,905,000
Market Cap
$70.12 million
Optionable
Optionable
Beta
1.32

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:ZYNE) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners